Vumerity and Affect lability - a phase IV clinical study of FDA data

Summary:

Affect lability is reported as a side effect among people who take Vumerity (diroximel fumarate), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Cymbalta, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Affect lability when taking Vumerity. It is created by eHealthMe based on reports of 9,775 people who have side effects when taking Vumerity from the FDA, and is updated regularly.

What is Vumerity?

Vumerity has active ingredients of diroximel fumarate. eHealthMe is studying from 9,781 Vumerity users. Check the latest studies of Vumerity.

What is Affect lability?

Affect lability (emotional incontinence) is found to be associated with 780 drugs and 811 conditions by eHealthMe. Check the latest studies of Affect lability.

On Jan, 03, 2026

9,775 people reported to have side effects when taking Vumerity.
Among them, 6 people (0.06%) have Affect lability.

Among these 6 people:

How long have people been on Vumerity when they have Affect lability? *

What is the gender of people who have Affect lability when taking Vumerity? *

female: 100 %
male: 0.0 %

What is the age of people who have Affect lability when taking Vumerity? *

What are other drugs people take besides Vumerity? *

Cymbalta: 1 person, 16.67%

What are other side effects people have besides Affect lability? *

Insomnia (sleeplessness): 2 people, 33.33%
Nausea And Vomiting: 2 people, 33.33%
Hot Flush (sudden feelings of heat): 2 people, 33.33%
Itching: 2 people, 33.33%
Abdominal Discomfort: 2 people, 33.33%
Skin Burning Sensation: 1 person, 16.67%
Gastric Disorder (disease of stomach): 1 person, 16.67%
Agitation (state of anxiety or nervous excitement): 1 person, 16.67%
Anger: 1 person, 16.67%
Bone Pain: 1 person, 16.67%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 66.67%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Vumerity and have Affect lability?

- Check whether Affect lability is associated with a drug or a condition (FREE)
- Predict drug outcomes for up to one year with AI (FREE)
- Get an AI agent to monitor your drugs continuously (FREE)

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vumerity:

Vumerity (9,781 reports)

Affect lability treatments and more:

Affect lability (13,491 reports)

Browse all side effects of Vumerity:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Affect lability:

Affect lability (780 drugs)

Browse all the conditions that are associated with Affect lability:

Affect lability (811 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on diroximel fumarate (the active ingredients of Vumerity) and Vumerity (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.